Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press11110.17650/1726-9776-2013-9-3-17-23DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиIDENTIFICATION OF PROGNOSTIC FACTORS OF THE EFFICIENCY OF BEVACIZUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CANCERОПРЕДЕЛЕНИЕ ФАКТОРОВ ПРОГНОЗА ЭФФЕКТИВНОСТИ ТЕРАПИИ БЕВАЦИЗУМАБОМ У БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ ПОЧЕЧНО-КЛЕТОЧНЫМ РАКОМAlekseyevB. Ya.АлексеевБ. Я.Russian Federation
Department of Urology with Course of Urologic Oncology
Department of Urology with Course of Urologic Oncology
кафедра урологии с курсом онкоурологии
dr.kalpinskiy@rambler.ruNyushkoK. M.НюшкоК. М.Russian Federationdr.kalpinskiy@rambler.ruKlimenkoA. A.КлименкоА. А.Russian Federationdr.kalpinskiy@rambler.ruAnzhiganovaYu. V.АнжигановаЮ. В.Russian Federationdr.kalpinskiy@rambler.ruVarlamovS. A.ВарламовС. А.Russian Federationdr.kalpinskiy@rambler.ruBichurinaS. A.БичуринаС. А.Russian Federationdr.kalpinskiy@rambler.ruVasilyevL. A.ВасильевЛ. А.Russian Federationdr.kalpinskiy@rambler.ruArkhipovA. V.АрхиповА. В.Russian Federationdr.kalpinskiy@rambler.ruGurinaL. I.ГуринаЛ. И.Russian Federationdr.kalpinskiy@rambler.ruLeonovO. V.ЛеоновО. В.Russian Federationdr.kalpinskiy@rambler.ruP.A. Herzen Moscow Oncology Research InstituteМНИОИ им П.А. ГерценаPeoples’ Friendship University of Russia, MoscowФПК МР РУДН, МоскваRussian Radiology Research Center, MoscowРНЦРР, МоскваKrasnoyarsk Territorial Clinical Oncology DispensaryКрасноярский краевой клинический онкологический диспансерAltai Territorial Oncology Dispensary, BarnaulАлтайский краевой онкологический диспансер, БарнаулRegional Clinical Oncology Dispensary, BlagoveshchenskОбластной клинический онкологический диспансер, БлаговещенскS.M. Kirov Military Medical Academy, Saint PetersburgВМА им. С.М. Кирова, Санкт-ПетербургArkhangelsk Regional Clinical Oncology DispensaryАрхангельский областной клинический онкологический диспансерPrimorye Territorial Oncology Dispensary, VladivostokПриморский краевой онкологический диспансер, ВладивостокClinical Oncology Dispensary, OmskКлинический онкологический диспансер, Омск300920139317232707201427072014https://oncourology.abvpress.ru/oncur/article/view/111metastatic renal-cell cancertargeted therapyangiogenesis inhibitorsprognostic factorsbevacizumabAvastinметастатический почечно-клеточный рактаргетная терапияингибиторы ангиогенезафакторы прогнозабевацизумабАвастин1. Hollingsworth J.M., Miller D.C., Daignault S., Hollenbeck B.K. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331–4.Hollingsworth J.M., Miller D.C., Daignault S., Hollenbeck B.K. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331–4.2. Злокачественные новообразования в России в 2011 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2013.Злокачественные новообразования в России в 2011 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2013.3. Keane T., Gillatt D., Evans C.P., Tubaro A. Current and future trends in treatment of renal cancer. Eur Urol 2007;Suppl 6:374–84.Keane T., Gillatt D., Evans C.P., Tubaro A. Current and future trends in treatment of renal cancer. Eur Urol 2007;Suppl 6:374–84.4. Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.5. Di Lorenzo G., Autorino R., Sternberg C.N. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009;56:959–71.Di Lorenzo G., Autorino R., Sternberg C.N. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009;56:959–71.6. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–6.Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–6.7. Motzer R.J., Bukowski R.M., Figlin R.A. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113:1552–8.Motzer R.J., Bukowski R.M., Figlin R.A. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113:1552–8.8. Rini B.I., Cohen D.P., Lu D. et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Natl Cancer Inst 2011;103:763–73.Rini B.I., Cohen D.P., Lu D. et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Natl Cancer Inst 2011;103:763–73.9. Karakiewicz P.I., Sun M., Bellmunt J. et al. Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the motzer criteria. Еur Urol 2011;60:48–56.Karakiewicz P.I., Sun M., Bellmunt J. et al. Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the motzer criteria. Еur Urol 2011;60:48–56.10. Ficarra V., Brunelli M., Cheng L. et al. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol 2010;58:655–68.Ficarra V., Brunelli M., Cheng L. et al. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol 2010;58:655–68.